Results 121 to 130 of about 27,974 (255)

Visceral Leishmaniasis in an Immunocompromised Patient: Diagnostic Bone Marrow Cytomorphology [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2017
Manjari Kishore, Garima Baweja Madaan
doaj   +1 more source

Germline TP53 Mutations Causing Diamond–Blackfan Anemia: A French Report

open access: yesPediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Diamond–Blackfan anemia is a rare congenital erythroblastopenia typically caused by mutations in ribosomal protein genes. Recently, gain‐of‐function mutations in TP53 have been identified as a novel cause of Diamond–Blackfan anemia. We report two French patients who both harbored a heterozygous TP53 deletion (NM_000546.5: c.1077delA; p ...
Rafael Moisan   +6 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

open access: yesAmerican Journal of Hematology, Volume 101, Issue 7, Page 1494-1506, July 2026.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper   +546 more
wiley   +1 more source

Platelet dysfunction in chronic kidney disease arises from bone marrow remodeling and megakaryocyte reprogramming. [PDF]

open access: yesBlood Adv
Carminita E   +17 more
europepmc   +1 more source

Assessing bleeding risk by thromboelastography when automated platelet count fails due to giant platelets. [PDF]

open access: yesBlood Vessel Thromb Hemost
Ye Z   +7 more
europepmc   +1 more source

What's Your Diagnosis? A Case of Extreme Thrombocytosis in a Dog

open access: yes
Veterinary Clinical Pathology, EarlyView.
Stephanie F. Anderson   +5 more
wiley   +1 more source

D‐Allulose as a Low‐Calorie Sweetener: A 30‐Day Randomized, Double‐Blind Study on Gastrointestinal Tolerance and Systemic Safety to Support Its Application in Healthy Diets

open access: yesFood Science &Nutrition, Volume 14, Issue 7, July 2026.
This graphical abstract presents the key design and findings of a 30‐day trial evaluating the safety of fermented D‐allulose in healthy Chinese adults. Fifty eligible adults were randomized to receive either low‐dose (24 g/day, n = 24) or high‐dose (36 g/day, n = 26) D‐allulose for 30 days.
Lijuan Qi   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy